<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="44185">Methotrexate</z:chebi> (MTX) and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> have been widely used for the treatment of <z:hpo ids='HP_0002488'>acute leukemias</z:hpo> and <z:hpo ids='HP_0002665'>lymphomas</z:hpo> for over 30 years </plain></SENT>
<SENT sid="1" pm="."><plain>However, the optimal schedule of this combination is yet to be determined and a variety of schedules of the combination has been used </plain></SENT>
<SENT sid="2" pm="."><plain>We studied the cytotoxic effects of MTX and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> in combination against human <z:hpo ids='HP_0001909'>leukemia</z:hpo> cell lines at various schedules in vitro </plain></SENT>
<SENT sid="3" pm="."><plain>The effects of the combinations at the concentration of drug that produced 80% cell growth inhibition (IC(80)) were analyzed using the isobologram method of Steel and Peckham </plain></SENT>
<SENT sid="4" pm="."><plain>Simultaneous exposure to MTX and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> for 3 days produced antagonistic effects in human T cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>, MOLT-3 and CCRF-CEM, B cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">BALL</z:e>-1, Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, Daudi, promyelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60 and <z:e sem="disease" ids="C0856536" disease_type="Neoplastic Process" abbrv="">Philadelphia chromosome-positive</z:e> <z:hpo ids='HP_0001909'>leukemia</z:hpo>, K-562 cells </plain></SENT>
<SENT sid="5" pm="."><plain>Simultaneous exposure to MTX and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> for 24 h produced antagonistic effects, sequential exposure to MTX for 24 h followed by <z:chebi fb="0" ids="28680">cytarabine</z:chebi> for 24 h produced synergistic effects, and the reverse sequence produced additive effects in both CCRF-CEM and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-60 cells </plain></SENT>
<SENT sid="6" pm="."><plain>Sequential exposure to MTX for 24 h followed by <z:chebi fb="0" ids="28680">cytarabine</z:chebi> for 3 days also produced synergistic effects in MOLT-3 cells </plain></SENT>
<SENT sid="7" pm="."><plain>Cell cycle analysis supported these observations </plain></SENT>
<SENT sid="8" pm="."><plain>Our findings suggest that the simultaneous administration of MTX and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> is not appropriate and the sequential administration of MTX followed by <z:chebi fb="0" ids="28680">cytarabine</z:chebi> may be the optimal schedule of this combination </plain></SENT>
</text></document>